Cytokinetics Inc (NASDAQ: CYTK) on Tuesday, plunged -1.09% from the previous trading day, before settling in for the closing price of $66.29. Within the past 52 weeks, CYTK’s price has moved between $25.98 and $110.25.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 12.30% over the past five years. The company achieved an average annual earnings per share of 18.27%. With a float of $100.94 million, this company’s outstanding shares have now reached $101.64 million.
Let’s look at the performance matrix of the company that is accounted for 423 employees.
Cytokinetics Inc (CYTK) Insider Updates
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Cytokinetics Inc is 3.48%, while institutional ownership is 108.16%. The most recent insider transaction that took place on Apr 09 ’24, was worth 2,422,918. In this transaction EVP Research & Development of this company sold 32,605 shares at a rate of $74.31, taking the stock ownership to the 138,567 shares. Before that another transaction happened on Mar 05 ’24, when Company’s EVP Research & Development sold 32,604 for $67.56, making the entire transaction worth $2,202,606. This insider now owns 138,973 shares in total.
Cytokinetics Inc (CYTK) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around 18.27% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 15.00% during the next five years compared to -22.79% drop over the previous five years of trading.
Cytokinetics Inc (NASDAQ: CYTK) Trading Performance Indicators
Cytokinetics Inc (CYTK) is currently performing well based on its current performance indicators. A quick ratio of 6.12 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 910.67.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -5.45, a number that is poised to hit -1.14 in the next quarter and is forecasted to reach -3.19 in one year’s time.
Technical Analysis of Cytokinetics Inc (CYTK)
Cytokinetics Inc (NASDAQ: CYTK) saw its 5-day average volume 1.28 million, a negative change from its year-to-date volume of 2.98 million. As of the previous 9 days, the stock’s Stochastic %D was 15.32%. Additionally, its Average True Range was 3.11.
During the past 100 days, Cytokinetics Inc’s (CYTK) raw stochastic average was set at 43.31%, which indicates a significant increase from 6.93% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 37.37% in the past 14 days, which was lower than the 117.07% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $70.79, while its 200-day Moving Average is $50.79. Nevertheless, the first resistance level for the watch stands at $67.71 in the near term. At $69.85, the stock is likely to face the second major resistance level. The third major resistance level sits at $70.94. If the price goes on to break the first support level at $64.48, it is likely to go to the next support level at $63.39. Assuming the price breaks the second support level, the third support level stands at $61.25.
Cytokinetics Inc (NASDAQ: CYTK) Key Stats
Market capitalization of the company is 6.86 billion based on 104,576K outstanding shares. Right now, sales total 7,530 K and income totals -526,240 K. The company made 1,670 K in profit during its latest quarter, and -136,900 K in sales during its previous quarter.
